Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| 1 | 11-10-2025 | 09-30-2025 | 10-Q | |
| 2 | 08-11-2025 | 06-30-2025 | 10-Q | |
| 3 | 05-15-2025 | 03-31-2025 | 10-Q | |
| 4 | 03-27-2025 | 12-31-2024 | 10-K | |
| 5 | 11-20-2024 | 09-30-2024 | 10-Q |
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Wells Fargo analyst Derek Archila upgrades Septerna (NASDAQ:SEPN) from Equal-Weight to Overweight and raises the price targe...
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Septerna (NASDAQ:SEPN) with a Buy and raises the price target f...
Septerna (NASDAQ:SEPN) reported quarterly earnings of $0.18 per share which met the analyst consensus estimate. This is a 102.1...
Cantor Fitzgerald analyst Josh Schimmer reiterates Septerna (NASDAQ:SEPN) with a Overweight and maintains $25 price target.
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Septerna (NASDAQ:SEPN) with a Buy and maintains $26 price target.
Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) ...
Septerna (NASDAQ:SEPN) reported quarterly losses of $(0.56) per share which missed the analyst consensus estimate of $(0.34) by...
Septerna gains Buy rating as HC Wainwright highlights undervaluation, strong pipeline, and key partnership with Novo Nordisk in...
